Ferroptosis of chondrocytes is a significant contributor to osteoarthritis (OA), for which there is still a lack of safe and effective therapeutic drugs targeting ferroptosis. Here, we screen for anti-ferroptotic drugs in Food and Drug Administration (FDA)-approved drug library via a high-throughput manner in chondrocytes. We identified a group of FDA-approved anti-ferroptotic drugs, among which vitamin K showed the most powerful protective effect. Further study demonstrated that vitamin K effectively inhibited ferroptosis and alleviated the extracellular matrix (ECM) degradation in chondrocytes. Intra-articular injection of vitamin K inhibited ferroptosis and alleviated OA phenotype in destabilization of the medial meniscus (DMM) mouse model. Mechanistically, transcriptome sequencing and knockdown experiments revealed that the anti-ferroptotic effects of vitamin K depended on growth arrest-specific 6 (Gas6). Furthermore, exogenous expression of Gas6 was found to inhibit ferroptosis through the AXL receptor tyrosine kinase (AXL)/phosphatidylinositol 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) axis. Together, we demonstrate that vitamin K inhibits ferroptosis and alleviates OA progression via enhancing Gas6 expression and its downstream pathway of AXL/PI3K/AKT axis, indicating vitamin K as well as Gas6 to serve as a potential therapeutic target for OA and other ferroptosis-related diseases.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

Objective To observe the clinical efficacy of Redo-Bentall surgery in the reoperation of aortic root lesions.Methods A retrospective analysis was performed on 46 patients who underwent Redo-Bentall surgery for aortic root lesions in our department from June 2010 to April 2022.They were 35 males and 11 females,at a mean age of 43.37±12.79 years,in 4.96±6.76 years since the last operation.General clinical data in perioperative period and during follow-up were collected and analyzed.Kaplan-Meier survival analysis was used to compare the survival rates of each etiological group.Results There were 9 cases of central end otitis,12 cases of Behset's disease,and 25 cases of other causes.After operation,4 cases(8.70％)experienced cardiac arrest,4 cases(8.70％)renal failure,2 cases(4.35％)gastrointestinal bleeding,2 cases(4.35％)new third-degree atrioventricular block and 2 cases(4.35％)permanent pacemaker placement.In perioperative period,3 cases(6.52％)died in hospital.During a mean follow-up of 5.03±3.27 years after discharge,5 cases(11.63％)were lost to follow-up,1 case died(2.33％),1 case had lacunar infarction(2.33％),and no severe bleeding or embolism complications was observed in the rest patients.The long-term survival rate was significantly lower in the endocarditis group(62.3％)and the Behcet's disease group(70％)than the other etiological groups(80％,P＜0.05).Conclusion The application of Redo-Bentall in the reoperation of aortic root lesions is safe and effective,but the survival rate is quite lower in the patients with infective endocarditis and Behcet's disease.